Axsome Therapeutics (AXSM) to Release Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) will issue its quarterly earnings data before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of ($1.22) per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 20th. The company reported ($0.73) earnings per share for the quarter, beating the consensus estimate of ($1.21) by $0.48. The company had revenue of $71.53 million for the quarter, compared to analyst estimates of $70.38 million. Axsome Therapeutics had a negative return on equity of 70.67% and a negative net margin of 88.41%. On average, analysts expect Axsome Therapeutics to post $-4 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Axsome Therapeutics Stock Up 0.8 %

Shares of AXSM stock opened at $74.80 on Friday. The stock’s 50 day simple moving average is $74.41 and its 200 day simple moving average is $75.42. Axsome Therapeutics has a twelve month low of $55.02 and a twelve month high of $98.40. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.52 and a current ratio of 3.63. The company has a market capitalization of $3.55 billion, a price-to-earnings ratio of -14.38 and a beta of 1.13.

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 24,662 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Roger Jeffs sold 29,976 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the completion of the transaction, the director now directly owns 120,756 shares of the company’s stock, valued at approximately $8,416,693.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Mark L. Jacobson sold 24,662 shares of Axsome Therapeutics stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The disclosure for this sale can be found here. Corporate insiders own 24.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on AXSM. Citigroup raised their price objective on shares of Axsome Therapeutics from $125.00 to $127.00 and gave the stock a “buy” rating in a research note on Tuesday, March 26th. Cantor Fitzgerald restated an “overweight” rating and set a $107.00 price objective on shares of Axsome Therapeutics in a report on Wednesday, April 10th. Guggenheim increased their target price on shares of Axsome Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Piper Sandler boosted their price target on Axsome Therapeutics from $90.00 to $113.00 and gave the company an “overweight” rating in a research note on Tuesday, January 16th. Finally, Morgan Stanley upgraded Axsome Therapeutics from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $90.00 to $115.00 in a research report on Monday, April 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $122.00.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.